{"id":812232,"date":"2025-02-12T14:48:06","date_gmt":"2025-02-12T19:48:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare-utilization-with-barostim\/"},"modified":"2025-02-12T14:48:06","modified_gmt":"2025-02-12T19:48:06","slug":"cvrx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare-utilization-with-barostim","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-announces-new-real-world-evidence-demonstrating-significant-reductions-in-healthcare-utilization-with-barostim\/","title":{"rendered":"CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim"},"content":{"rendered":"

\nNew real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
\n<\/h2>\n
\n

MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) — CVRx, Inc<\/u><\/a>. (NASDAQ: CVRX) (\u201cCVRx\u201d), a commercial-stage medical device company, announced today\u00a0the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The study demonstrated large and statistically significant reductions in hospital visits (hospitalizations and emergency department visits) and length of stay after Barostim implantation, compared to before. The research was published simultaneously and is available now in the Journal of Cardiac Failure<\/em>.<\/p>\n

\u201cDespite contemporary medications, the clinical and economic burden of heart failure remains unacceptably high. This new study showing significant reductions in real-world healthcare utilization associated with the Barostim implant is critically important for clinicians and payers when considering this device for their patients,\u201d said Jacob Abraham, MD, Section Head of Advanced Heart Failure at Providence Heart Institute in Portland, Ore. \u201cWhile we know Barostim plus medications demonstrates long-term improvements in symptoms and quality of life, we now have compelling real-world evidence supporting a significant reduction in healthcare utilization as well.\u201d<\/p>\n

This analysis was performed using data from the Premier Healthcare Database, a large all-payer database including data from more than 1,300 institutions. Three hundred and six (306) Barostim patients were identified in the data set. Comparisons were performed for the 12 months prior to Barostim implant and for an average of almost two years post-implant (1.92\u00b11.87 years). Length of stay was found to be significantly reduced. Hospital visits (hospitalizations and emergency department visits) were categorized as all-cause, cardiovascular, and heart failure related. The analysis found:<\/p>\n